P1/2, N=60, Recruiting, Beijing Biotech

P2, N=38, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

Treatment with the KXD regimen (carfilzomib, cyclophosphamide, dexamethasone) resulted in transient disease stabilization for approximately two months, followed by further progression. In addition, infiltration of CD138-positive plasma cell-like tumor cells with λ light chain restriction was observed in the gastric lamina propria, consistent with extramedullary disease (EMD). The final diagnosis was relapsed MM complicated by sPCL, gastric mucosal extramedullary plasmacytic infiltration, and synchronous moderately differentiated intramucosal papillary adenocarcinoma.

P2, N=25, Recruiting, The First Hospital of Jilin University

P1, N=40, Not yet recruiting, National Cancer Institute (NCI)

To define mechanisms of resistance, we performed single-cell RNA sequencing on orthotopic TNBC patient-derived xenografts during a cycle of treatment with doxorubicin and cyclophosphamide (AC). Thus, the up-regulation of C15ORF48 blunts ROS accumulation and induces resistance to chemotherapy in the basal cell subpopulations. Our findings identify C15ORF48 as a potential therapeutic target for overcoming AC resistance in TNBC.

P2, N=41, Recruiting, Milton S. Hershey Medical Center | Not yet recruiting --> Recruiting

P1, N=5, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2028 --> Aug 2027

Based on ex vivo drug sensitivity testing, lomustine was initiated as rescue chemotherapy, achieving a second complete remission...Key clinical message: This case highlights the fact that progression from primary mediastinal to multicentric lymphoma may be associated with a poor prognosis in dogs. Radiation therapy demonstrated potential efficacy and warrants further investigation as a treatment option for canine mediastinal lymphoma.

High-dose etoposide (1.2 g/m2) demonstrated superior efficacy and safety compared to high-dose cyclophosphamide (3.0 g/m2) for stem cell mobilization in NDMM patients. Based on these findings, etoposide may be considered a more effective and safer option for stem cell mobilization in clinical practice.The clinical trial was registered on 24/08/2022 (clinical trial identifier NCT05517213).

This case represents, to our knowledge, one of the very few-if not the first-reported instances of successful HSCT for JMML in a patient with TAR syndrome. It underscores the importance of vigilant surveillance in TAR patients for potential malignant transformation and demonstrates the curative potential of HSCT in rare congenital-hematologic overlap syndromes.

P=N/A, N=96, Not yet recruiting, Assiut University